Loading…
Kazia Therapeutics Limited is projected to rise to $13.48 by 2027, a +11% move from its current price of $12.16. KZIA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.63 | $12.17 | $12.72 | +0.04% |
| May 30 | $11.42 | $12.17 | $12.97 | +0.08% |
| May 31 | $11.27 | $12.18 | $13.16 | +0.12% |
| Jun 1 | $11.14 | $12.18 | $13.32 | +0.17% |
| Jun 2 | $11.02 | $12.19 | $13.47 | +0.21% |
| Jun 3 | $10.92 | $12.19 | $13.60 | +0.25% |
| Jun 4 | $10.83 | $12.20 | $13.73 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.83 | $12.20 | $13.73 | +0.29% |
| Week 2 | $10.34 | $12.23 | $14.46 | +0.58% |
| Week 3 | $9.99 | $12.27 | $15.06 | +0.87% |
| Week 4 | $9.70 | $12.30 | $15.59 | +1.16% |
| Week 5 | $9.46 | $12.34 | $16.08 | +1.45% |
| Week 6 | $9.25 | $12.37 | $16.54 | +1.75% |
| Week 7 | $9.07 | $12.41 | $16.98 | +2.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Its lead development candidate paxalisib is a small molecule brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary CNS lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.
The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited (KZIA) is an oncology-focused biotechnology company with a patient-centric pipeline centered on paxalisib and EVT801. The current price is $12.16 per share, and the market capitalization stands at $138.95M. The stock is ranked 4019 by market cap among visible listings.
A major floor 58.8% below — a decisive break under it would weaken the trend.
The nearest floor, 17.8% below — buyers have tended to step in here.
The nearest ceiling, 18.7% above — a clean break opens room to run.
A major ceiling 36.8% above — clearing it would confirm fresh momentum.
Key KZIA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KZIA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.89 | Sell | $12.71 | Sell |
| MA 10 | $13.01 | Sell | $12.92 | Sell |
| MA 20 | $13.30 | Sell | $12.74 | Sell |
| MA 50 | $10.72 | Buy | $11.31 | Buy |
| MA 100 | $8.80 | Buy | $9.99 | Buy |
| MA 200 | $8.53 | Buy | $9.33 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.18 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -130.67 | Sell |
| Williams %R (14) | -96.61 | Info |
| MACD (12,26,9) | -0.31 | Sell |
| ROC (12) | -15.79 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 3.39 | Buy |
| TRIX (15) | 1.04 | Buy |
| Awesome (5,34) | 0.70 | Buy |
| Ultimate (7,14,28) | 40.46 | Neutral |
| Momentum (10) | -2.14 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 12.86 | Sell |
| ADX (14) | 23.07 | Sell |
| ATR (14) | 0.52 | Info |
In the near term, the sentiment is BULLISH with a RSI14 reading of 50. The stock trades above its key moving averages, with a SMA50 of $10.72 and a SMA200 of $8.53. Support is shown at $10.00 and resistance at $14.44, framing a near-term trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.00 | $12.16 | $15.30 | 0% | Neutral | |
| $10.03 | $13.48 | $19.53 | +11% | Neutral | |
| $9.72 | $13.71 | $20.95 | +13% | Neutral | |
| $11.25 | $16.53 | $26.33 | +36% | Bullish | |
| $15.17 | $23.13 | $38.16 | +90% | Bullish | |
| $16.30 | $25.72 | $43.73 | +112% | Bullish | |
| $16.22 | $26.44 | $46.18 | +117% | Bullish | |
| $15.02 | $25.26 | $45.20 | +108% | Bullish | |
| $15.47 | $26.80 | $49.03 | +120% | Bullish | |
| $18.65 | $33.27 | $62.12 | +174% | Bullish | |
| $23.87 | $48.87 | $99.33 | +302% | Bullish | |
| $48.81 | $108.48 | $248.68 | +792% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.00 | $12.16 | $14.35 | +0.00% |
| June 2026 | $10.34 | $12.31 | $15.14 | +1.25% |
| July 2026 | $10.45 | $12.63 | $15.86 | +2.55% |
| August 2026 | $9.85 | $12.03 | $15.36 | -4.71% |
| September 2026 | $9.30 | $11.46 | $14.83 | -4.75% |
| October 2026 | $9.47 | $11.77 | $15.42 | +2.76% |
| November 2026 | $9.51 | $11.91 | $15.76 | +1.18% |
| December 2026 | $9.08 | $11.45 | $15.30 | -3.90% |
Click any year to see its month-by-month KZIA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, KZIA is projected to trade between $5.00 and $15.30, averaging $12.16 — a potential gain of 0% from today's $12.16. Price action looks broadly range-bound.
Kazia Therapeutics Limited's 2027 outlook centres on $13.48, within a $10.03 to $19.53 range. That is up +11% on the projected 2026 average. That marks a +11% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, KZIA could reach as high as $20.95, with a base case around $13.71 and support toward $9.72 — roughly +13% from $12.16. Price action looks broadly range-bound.
Expect KZIA to range from $11.25 to $26.33 through 2029. The $16.53 average target implies a +36% move from current prices. That is up +21% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The KZIA price prediction for 2030 points to an average of $23.13 (low $15.17, high $38.16) — a potential gain of +90% on today's $12.16. Momentum favours further upside here.
In 2031, KZIA is projected to trade between $16.30 and $43.73, averaging $25.72 — a potential gain of +112% from today's $12.16. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Kazia Therapeutics Limited's 2032 outlook centres on $26.44, within a $16.22 to $46.18 range. That is up +3% on the projected 2031 average. That marks a +117% change versus current levels. Momentum favours further upside here.
By 2033, KZIA could reach as high as $45.20, with a base case around $25.26 and support toward $15.02 — roughly +108% from $12.16. Buyers look set to stay in control over this stretch.
Expect KZIA to range from $15.47 to $49.03 through 2034. The $26.80 average target implies a +120% move from current prices. That is up +6% on the projected 2033 average. Momentum favours further upside here.
The KZIA price prediction for 2035 points to an average of $33.27 (low $18.65, high $62.12) — a potential gain of +174% on today's $12.16. Buyers look set to stay in control over this stretch.
In 2040, KZIA is projected to trade between $23.87 and $99.33, averaging $48.87 — a potential gain of +302% from today's $12.16. That is up +47% on the projected 2035 average. Momentum favours further upside here.
Kazia Therapeutics Limited's 2050 outlook centres on $108.48, within a $48.81 to $248.68 range. That is up +122% on the projected 2040 average. That marks a +792% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in KZIA today (≈ 82.236842 KZIA) could be worth
$8,920.74
+$7,920.74 (+792%) by 2050 · US Dollar
Based on the average projected KZIA price of $108.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KZIAwould be worth at today's price.
$1,000 invested in KZIA on May 27, 2025 (≈ 267.379678 KZIA) would be worth
$3,251.34
+$2,251.34 (+225.1%) today · 3.25× · US Dollar
Based on a KZIA entry price of $3.74 vs. today's $12.16.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.97 | $937.55 | -6.2% |
| 1 month ago | $11.95 | $1,017.57 | +1.8% |
| 3 months ago | $8.85 | $1,374.01 | +37.4% |
| 6 months ago | $10.55 | $1,152.61 | +15.3% |
| 1 year ago | $3.74 | $3,251.34 | +225.1% |
| All time (5.0y) ago | $480.5 | $25.31 | -97.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KZIA forecast.
Our base-case forecast reaches $24.00 around 2031.
Implied market cap at $24.00: $274.25M
The multi-year forecast shows a path of rising averages and returns. In 2026, the average price is $12.16 with a min of $5.00 and a max of $15.30, and ROI of 0% (sentiment NEUTRAL). By 2027 the average is $13.48 (min $10.03, max $19.53) with ROI 10.9%.
In 2028 the average is $13.71 (min $9.72, max $20.95) with ROI 12.8%. The 2029 forecast shows an average of $16.53 (min $11.25, max $26.33) and ROI 35.9%. The outlook strengthens into 2030–2035, with 2030 average $23.13 (min $15.17, max $38.16) and ROI 90.2%, 2031 average $25.72 (min $16.30, max $43.73) ROI 111.5%, 2032 average $26.44 (min $16.22, max $46.18) ROI 117.5%, 2033 average $25.26 (min $15.02, max $45.20) ROI 107.7%, 2034 average $26.80 (min $15.47, max $49.03) ROI 120.4%, 2035 average $33.27 (min $18.65, max $62.12) ROI 173.6%, followed by strong upward targets into 2040 with average $48.87 (min $23.87, max $99.33) ROI 301.9%, and by 2050 an average of $108.48 (min $48.81, max $248.68) ROI 792.1%.
Sentiment remains BULLISH in the long term. These figures are estimates and not guarantees, reflecting potential paths for the asset under varying conditions.
Tap a question to reveal the answer.
The forecast shows an average price of $23.13 in 2030, with a min of $15.17 and a max of $38.16, and an ROI of 90.2%. The sentiment for 2030 is BULLISH.
Long-term forecasts imply upside, with 2035 average $33.27 and 2050 average $108.48, corresponding to ROIs of 173.6% and 792.1% respectively. The 2026 outlook is 12.16 on average with 0% ROI and NEUTRAL sentiment, indicating uncertainty and risk.
Yes. The 2035 forecast shows a max of $62.12 and an average of $33.27, suggesting a path to around $60 within the year if the high end is realized.
For 2026, the average forecast price is $12.16, with a min of $5.00 and a max of $15.30. The ROI is 0% and sentiment is NEUTRAL.
The 2050 forecast shows an average price of $108.48 (min $48.81, max $248.68) with an ROI of 792.1% and sentiment BULLISH.
Kazia Therapeutics Limited Community Discussion
0Share your Kazia Therapeutics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.